Rapid increase in fibroblast growth factor 21 in protein malnutrition and its impact on growth and lipid metabolism

Yori Ozaki1, Kenji Saito2, Kyoko Nakazawa2, Morichika Konishi3, Nobuyuki Itoh4, Fumihiko Hakuno5, Shin-Ichiro Takahashi5, Hisanori Kato6 and Asako Takenaka1*

1Department of Agricultural Chemistry, School of Agriculture, Meiji University, Kawasaki, Kanagawa 214-8571, Japan
2Corporate Sponsored Research Program ‘Food for Life’, Organization for Interdisciplinary Research Projects, The University of Tokyo, Bunkyo, Tokyo 113-8657, Japan
3Department of Microbial Chemistry, Kobe Pharmaceutical University, Kobe, Hyogo 658-8558, Japan
4Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Sakyo, Kyoto 606-8501, Japan
5Department of Animal Sciences and Applied Biological Chemistry, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Bunkyo, Tokyo 113-8657, Japan

(Submitted 30 January 2015 – Final revision received 2 June 2015 – Accepted 29 June 2015 – First published online 2 September 2015)

Abstract

Protein malnutrition promotes hepatic steatosis, decreases insulin-like growth factor (IGF)-I production and retards growth. To identify new molecules involved in such changes, we conducted DNA microarray analysis on liver samples from rats fed an isoenergetic low-protein diet for 8 h. We identified the fibroblast growth factor 21 gene (Fgf21) as one of the most strongly up-regulated genes under conditions of acute protein malnutrition (P < 0.05, false-discovery rate < 0.001). In addition, amino acid deprivation increased Fgf21 mRNA levels in rat liver-derived RL-54i cells (P < 0.01). These results suggested that amino acid limitation directly increases Fgf21 expression. FGF21 is a polypeptide hormone that regulates glucose and lipid metabolism. FGF21 also promotes a growth hormone-resistance state and suppresses IGF-I in steatosis in protein-malnourished animals.

Key words: DNA microarray analysis: Fibroblast growth factor 21: Low-protein diets: Protein malnutrition: Fgf21

Fibroblast growth factor (FGF) 21 is a member of the FGF superfamily, which is believed to act in an endocrine manner and to have pleiotropic effects on glucose and lipid metabolism. FGF21 was initially found to be preferentially expressed in the liver and later reported to be expressed in pancreas, testis, adipose tissue and muscle as well. Gene expression in the liver and the circulating level of FGF21 are reportedly increased by means of fasting, a high-fat/low-carbohydrate ketogenic diet and endoplasmic reticulum (ER) stress, and men with obesity, type 2 diabetes and non-alcoholic fatty liver disease show elevated circulating FGF21 levels. Moreover, FGF21 expression is increased by mitochondrial myopathy, autophagy deficiency or mitochondrial uncoupling in skeletal muscle, and by cold exposure or β3-adrenergic stimulation in brown adipose tissue (BAT). In addition to these observations, the results of our present DNA microarray analysis revealed a very rapid up-regulation of Fgf21 expression in the liver of rats fed an isoenergetic low-protein diet. The increase in Fgf21 is reportedly mediated by activating transcription factor 4 (ATF4) during treatment with His-OH, which mimics amino acid deprivation, treatment with the anti-hyperglycaemic drug Metformin or ER stress. In addition, peroxisome proliferator-activated receptor-α (PPAR-α) regulates Fgf21 expression during fasting and ketosis.

Abbreviations: Epi-WAT, epididymal white adipose tissue; FGF, fibroblast growth factor; GH, growth hormone; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; KO, knockout; TKB, total ketone body; Tg, transgenic; WT, wild-type.

* Corresponding author: A. Takenaka, fax +81 44 934 7902, email takenaka@meiji.ac.jp
Impact of FGF21 in protein malnutrition

Growth retardation accompanied by decreased insulin-like growth factor (IGF)-I levels is a well-known symptom observed in protein-malnourished animals during the growth phase[17]. Moreover, animals fed low-protein diets show impaired glucose-induced insulin secretion[18–20]. Direct stimulation of hepatic IGF-I production by insulin treatment has been reported[21], however, our previous study showed that impaired insulin secretion is not the cause of decreased IGF-I and growth retardation in protein-malnourished animals[22], and the molecular mechanism underlying the decrease in IGF-I remains unknown. Although FGF21 is classified as a member of the FGF family, it has never been reported to promote growth in fibroblasts or in vivo[23]. Instead, Fgf21-transgenic (Tg) mice with increased plasma FGF21 concentration show significant growth retardation accompanied by suppression of growth hormone (GH) signalling, including down-regulation of IGF-I and up-regulation of IGF binding protein (IGFBP)-1, which sequesters IGF-I action[24]. Moreover, 1–3 d of FGF21 treatment decreases plasma IGF-I levels and increases liver Igfbp-1 mRNA levels in wild-type (WT) mice[24]. Therefore, up-regulated FGF21 seemed to have the potential to suppress IGF-I.

Liver steatosis is another major phenotype observed under protein malnutrition conditions in growing animals or patients with kwashiorkor, possibly in part due to impaired lipid release from the liver[25,26]. However, the effect of FGF21 on liver steatosis in protein malnutrition has not been studied. Contradictory results have been reported from several independent studies of FGF21 function in lipid metabolism. For example, Fgf21-Tg mice and recombinant FGF21 treatment showed that FGF21 stimulates lipolysis[5]. In addition, FGF21 promotes lipolysis during normal and recombinant FGF21 treatment showed that FGF21 stimulates lipolysis[5].

Similarly, FGF21 treatment suppresses lipolysis in obese (ob/ob) mice and in cultured adipocyte cells[29]. In the liver, FGF21 does not seem to regulate fasting-inducing hepatic TAG accumulation because no effect of Fgf21-KO has been observed on liver TAG levels[27]. On the contrary, treatment with recombinant FGF21 reverses liver steatosis in diet-induced obese (DIO) mice fed a high-fat diet[30,31]. Thus, the role of FGF21 in systemic lipid metabolism seems complicated, and its effect during protein malnutrition is unknown. Therefore, to investigate whether the up-regulation of FGF21 in protein malnutrition is responsible for growth retardation or liver steatosis, we fed an isonenergetic low-protein diet to Fgf21-KO mice and monitored their growth and IGF-I concentrations and lipid profiles.

**Methods**

**DNA microarray analysis**

Male Wistar strain rats were maintained under conditions described previously[22]. Six-week-old rats were fed a control diet (containing 15% casein as a protein source) or an isonenergetic low-protein diet (containing 5% casein) for 8 h. Because we had previously observed a significant increase in liver TAG accumulation in rats fed this regimen, we collected the rat livers after 16 h of starvation[22]. The complete composition of the experimental diet is given elsewhere[22]. Total RNA was extracted from the livers of three rats from each diet group using an RNasea mini kit (Qiagen), and the samples were prepared for hybridisation by using a GeneChip 3′ IVT express kit (Affymetrix) according to the manufacturers’ instructions. Each sample was hybridised to a GeneChip Rat Genome 230 2.0 Array (Affymetrix), and fluorescence signals were scanned with an Affymetrix GeneChip Scanner 3000 7G (Affymetrix). The raw data (.CEL files) were normalised with the robust multichip average algorithm by using ‘R’. The changes were judged as significant if the false-discovery rate (FDR) was lower than 0.05. Data sets with FDR < 0.05 were uploaded to the Ingenuity Pathway Analysis (IPA) program (Ingenuity Systems) for pathway and global functional analyses. All microarray data have been deposited in the Gene Expression Omnibus database (accession number: GSE64970).

Liver Igf1 mRNA, plasma IGF-I and plasma and liver TAG levels of the rats used for the microarray analysis were determined as described previously[22]. Plasma and liver cholesterol and phospholipid levels were assessed with a Cholesterol E test (Wako Pure Chemicals) and Phospholipid C test (Wako Pure Chemicals), respectively. The animal experiment was approved by the Meiji University Institutional Animal Care and Use Committee (permission number: IACUC11-0010).

**Quantitative real-time RT-PCR**

First-strand complementary DNA (cDNA) synthesis and quantitative real-time PCR were performed for livers of 4–5 rats (including those used for microarray analysis) as described previously[22]. The primer sequences were as follows: for the rat β-actin gene, forward primer 5′-GCGGACGTCGAGTTAAGATGA-3′ and reverse primer 5′-AGACAGCTACGGGACACACA-3′; for the rat Fgf21 gene, forward primer 5′-TCTCTGGGTGCTAAAGGTCT-3′ and reverse primer 5′-CAGGGCTACGATACGTTGA-3′; for the mouse β-actin gene, forward primer 5′-CTTGATGAAAAGATGAAGCTT-3′ and reverse primer 5′-GCGGACGTGGCTGGTTA-3′; for the mouse Fgf21 gene, forward primer 5′-TCCTGGAGGGCTGCTGAC-3′ and reverse primer 5′-GTGCTCATGCTGAGC-3′.

**RL-34 cells**

RL-34 cells were purchased from the Japanese Collection of Research Bioresources Cell Bank (JCRB0247). The cells were maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (FBS) and antibiotics at 37°C in a humid atmosphere containing 5% CO2. Before experimental treatment, the cells were cultured in minimum essential medium (MEM) containing 10% FBS. Subconfluent cells were serum-starved overnight in MEM containing 0.1% bovine serum albumin, further cultured in MEM with or without amino acids.
samples were obtained. The livers were excised, weighed, heparinised blood was collected via cardiac puncture, and plasma sodium pentobarbital (Somnopentyl; Kyoritsu Seiyaku), heparinised at 09.00 hours, the mice were anaesthetised with C57BL/6J WT (+/–) mice (27) were bred with C57BL/6j WT (Fgf21+/+) mice to obtain heterozygous Fgf21KO (Fgf21−/−) mice. The Fgf21−/− mice were then crossed to obtain Fgf21−/− and WT mice for the subsequent experiment. Genotyping of the animals was conducted as described previously (27). Animals were kept at 22–24°C under a 12 h (06:00–18:00 hours) light–dark cycle and fed a commercial pellet feed ad libitum (certified diet MF; Oriental Yeast) unless otherwise noted. All animals were allowed free access to tap water throughout the experiment.

Four- to five-week-old male Fgf21-KO (Fgf21−/−) and WT mice were housed individually in cages and trained to eat a control diet containing 20 % casein (20P) between 17.00 and 09.00 hours for 3 d, after which they were divided into two dietary groups. The 20P groups received the control diet, whereas the low-protein diet groups were fed an isoenergetic low-protein diet containing 5 % casein (5P) on the same schedule for 5 d. The compositions of the diets are shown in Table 1. On day 5 of the experimental feeding, heparinised blood was collected from the tail before feeding to measure FGF21 levels under fasting conditions. Subsequently, the mice were fed the respective diet ad libitum for another 5 d. On day 11 following 09.00 hours, the mice were anaesthetised with sodium pentobarbital (Somnopentyl; Kyoritsu Seiyaku), heparinised blood was collected via cardiac puncture, and plasma samples were obtained. The livers were excised, weighed, frozen in liquid N2 and stored at −80°C until analysis. Epididymal white adipose tissue (epi-WAT) and gastrocnemius tissue were also excised and weighed. The animal experiment was approved by the Meiji University Institutional Animal Care and Use Committee (permission number: IACUC14–0005).

### Measurements of plasma fibroblast growth factor 21, insulin-like growth factor-I, NEFA, total ketone bodies, TAG, cholesterol and phospholipid levels

Plasma FGF21 and IGF-I concentrations were assayed with a Mouse/Rat FGF21 Quantikine ELISA Kit (R&D Systems) and a Mouse/Rat IGF-I Quantikine ELISA Kit (R&D Systems), respectively, following the manufacturers’ instructions. Plasma NEFA, total ketone body (TKB), TAG, cholesterol and phospholipid levels were assayed with NEFA-SS (Eiken Chemical), Autokit Total Ketone Bodies (Wako Pure Chemicals), Triglyceride E test (Wako Pure Chemicals), Cholesterol E test (Wako Pure Chemicals) and Phospholipid C test (Wako Pure Chemicals), respectively.

### Statistical analysis

Student’s t test and Welch’s t test accounting for equal or unequal variances, respectively, were applied to compare the values between the two experimental groups shown in Fig. 1 (a)–(d), online Supplementary Table S1 and Fig. 2(a). Two-way ANOVA was carried out to evaluate the significant effects of FGF21, the low-protein diet and FGF21 × diet interaction on the values shown in Fig. 2(b)–(g), Fig. 3(a)–(h) and Table 2. Post hoc comparisons were performed with Scheffe’s F test when significant interaction of FGF21 × diet was observed with two-way ANOVA. A P value of <0.05 was considered significant. Statistical analyses were performed with Statcel Ver. 2 software (OMS Publishing).

### Results

#### Features of the rats used in the microarray analysis

Compared with rats fed the 15P diet, rats fed the 5P diet for 8 h followed by 16 h of starvation showed significantly lower body weight (P < 0.05), body weight gain (P < 0.01), liver weight (P < 0.05) and % liver weight (relative to body weight; P < 0.05; online Supplementary Table S1). Total food intake did not differ between the two groups (P = 0.241). Plasma IGF-I concentration was not statistically different (P = 0.381); however, the relative liver igf1 mRNA level was significantly lower in the 5P animals (P < 0.05).

The liver TAG and cholesterol concentrations in the 5P group were significantly higher than those in the 15P group (both P < 0.05; online Supplementary Table S1). The liver phospholipid concentration did not differ between the two groups (P = 0.525). The plasma cholesterol and phospholipid concentrations were significantly lower in the 5P group (both P < 0.05). The plasma TAG concentration also trended lower in the 5P group, although the difference did not reach statistical significance (P = 0.059).

#### Increase in Fgf21 expression with acute protein malnutrition

Microarray analysis identified Fgf21 as one of the ten most highly up-regulated genes in the liver of rats fed the low-protein diet.
diet for 8 h followed by 16 h of starvation (*P<0.05, FDR <0.001; see Fig. 1(a) and online Supplementary Table S2). Similar expression profiles were observed with quantitative real-time PCR analysis, although the differences did not reach statistical significance (P=0.055; see Fig. 1(b)). The plasma FGF21 level in 5P animals was significantly higher than that in 15P animals (*P<0.05; see Fig. 1(c)). Furthermore, Fgf21 mRNA levels increased in RL-34 rat liver cells cultured in amino acid-deprived medium for 24 h (*P<0.01; see Fig. 1(d)). Upstream analyses of the microarray data with the IPA program predicted activation of ATF4 (activation Z score = 2.189, *P value of overlap = 2.46E–09; online Supplementary Fig. S1). PPAR-α was also predicted to be significantly altered (activation Z score = 2.000, *P value of overlap = 2.02E–28); however, it was not judged as activated because the expression patterns of one third of the target genes were oriented in the opposite direction in terms of PPAR-α activation.

No suppression of plasma insulin-like growth factor-1 and growth by fibroblast growth factor 21 in protein malnutrition

Feeding the low-protein diet significantly increased plasma FGF21 levels in WT mice. This increase was >50-fold at day 5 in fasted animals and >10-fold at day 11 in animals fed *ad libitum* (both *P<0.01; see Fig. 2(a)). No FGF21 was detected in the plasma of the Fgf21-KO mice. The 5P diet suppressed growth to a similar extent in both WT and Fgf21-KO animals from day 2. Two-way ANOVA revealed significant effects of the 5P diet on this suppression (*P<0.05 for days 3, 4, 6 and 7; *P<0.01 for days 5, 8, 9, 10 and 11; see Fig. 2(b)), and final body weight was significantly lower in the 5P groups (Table 2). Plasma IGF-1 levels were also lower in the 5P groups, and no effect of FGF21 or diet x FGF21 interaction was observed on the differences (*P<0.001; see Fig. 2(c)). Total food intake during the experimental diet feeding was lower in the Fgf21-KO mice than in the WT mice; however, we observed no effect of diet on this decrease (see Table 2). The 5P diet increased liver *Igfbp-1* mRNA levels in both the presence and absence of FGF21 (*P<0.01; see Fig. 2(d)).

Protective effect of fibroblast growth factor 21 against obesity and liver steatosis during protein malnutrition

Both absolute liver weight and liver weight expressed by % body weight were significantly lower in the 5P animals (*P<0.001; see Fig. 2(e) and Table 2). The 5P diet did not affect the epi-WAT weight of the WT mice, but the epi-WAT weight was significantly increased in Fgf21-KO mice (see Fig. 2(f) and Table 2). Gastrocnemius weight did not differ among the four groups (see Fig. 2(g) and Table 2).

The absence of FGF21 significantly increased plasma NEFA and TAG levels (both *P<0.01; see Fig. 3(a) and (c)). Moreover, the 5P diet significantly suppressed plasma NEFA and TAG levels (both *P<0.001; see Fig. 3(a) and (c)). The 5P diet...
Discussion

The DNA microarray analysis in the present study identified Fgfg21 as one of the most highly up-regulated genes in the liver of rats fed a low-protein diet for 8 h. In agreement with the results of the microarray analysis and compared with control mice, WT mice fed an isoenergetic low-protein diet for 5 and 11 d showed significantly greater plasma FGF21 levels, which were consistent with the recently published work by Laeger et al.\textsuperscript{34}. The plasma FGF21 concentration of the animals fed the low-protein diet was higher in mice than in rats, likely due to...
to differences in species, age or the period during which the animals were fed the low-protein diet. We observed greater than 30- and 10-fold inductions in the mean values of plasma FGF21 concentration under starved and feeding ad libitum conditions, respectively.

Furthermore, the results of our in vitro experiment showed that Fgf21 mRNA levels increased in RL-34 hepatic cells cultured in amino acid-deprived medium. Thus, amino acid deprivation seems to increase Fgf21 directly. Moreover, our microarray analysis predicted significant activation of ATF4 in the liver of rats fed the low-protein diet for 8 h (online Supplementary Fig. S1). In addition, PPAR-α was predicted to be significantly altered, although the status was not judged as activated (online Supplementary Fig. S1). Therefore, the rapid induction of Fgf21 that we observed may also be mediated by the activation of ATF4, PPAR-α or both.

To our knowledge, there are no other microarray data on the liver of animals subjected to only 8 h of protein restriction and no data suggesting the activation of ATF4 and possibly PPAR-α under this condition. In addition to FGF21, some ATF4 target
genes, such as asparagine synthetase (Asns), phosphoserine
aminotransferase 1 (Psat1) and phosphoglycerate dehydro-
genase (Phgdh) are reportedly up-regulated by mitochondrial
uncoupling in the muscle[35] and were up-regulated in our
microarray data as well, whereas other stress-response genes[12]
mostly showed no up-regulation in our experiment. Thus, ATF4
may induce FGF21 in different tissues under various physiological
conditions that may alter protein metabolism. However,
although recent data have also demonstrated that both general
control nondepressible 2 (GCN2), an upstream regulator of
ATF4, and PPAR-α contribute to FGF21 regulation during
protein malnutrition, they do not seem to be the only factors
involved in FGF21 induction[24].

Protein deficiency induces a state of GH resistance[26].
Previously, high FGF21 levels in Fgf21-Tg mice were shown to
block GH action, which resulted in growth retardation[24]. In
these Fgf21-Tg mice, plasma IGF-I level is significantly
decreased and liver mRNA level of Igfbp-1, which sequesters
IGF-I action, is significantly increased. Notably, this phenotype
is also observed in protein-malnourished animals[17-37], which
led us to hypothesise that increased FGF21 induces GH resis-
tance and reduction in IGF-I activity followed by growth
retardation in protein-malnourished animals. Although we
identified FGF21 up-regulation in the livers of rats fed a low-
protein diet for 1 d, we applied a longer feeding period for
Fgf21-KO mice because we wanted to know whether increases
in FGF21 are responsible for growth retardation in protein
malnutrition. However, unlike Fgf21-Tg mice, Fgf21-KO mice
did not show rescue of growth retardation, reduced plasma
IGF-I concentration or increased Igfbp-1 mRNA level in the
liver, which demonstrated that increased FGF21 does not
promote a GH-resistance state under conditions of protein
malnutrition.

In addition, the basal level of FGF21 apparently does not
regulate IGF-I levels and growth because these parameters
were unaffected in Fgf21-KO animals fed the control diet.
Because DIO mice fed obesogenic high-fat/high-sucrose diets
are reportedly FGF21 resistant[38], it is likely that the feeding
status and physiological states of animals affect FGF21 sensi-
tivity. Thus, the seemingly different FGF21 actions previously
observed in Fgf21-Tg mice and presently observed in Fgf21-KO
mice may be related to differences in local FGF21 sensitivity.
In addition, although FGF21 has been postulated to be an
endocrine factor, whether it is present in the circulation in its
active form remains to be determined[23], and the mechanism
that suppresses IGF-I and growth under protein malnutrition
conditions remains unknown.

It is likely that both low-protein diet and basal FGF21 level
suppress lipolysis under sufficient protein conditions because
the low-protein diet suppressed plasma NEFA, whereas the
absence of FGF21 increased it. Consistent with our observa-
tions, FGF21 treatment decreases circulating NEFA in both lean
and obese mice[29,31,36], and FGF21 has been shown to sup-
press lipolysis in Fgf21-KO mice under fasting conditions[27].
However, increased FGF21 due to protein restriction appears
not to suppress lipolysis because feeding the low-protein
diet reduced plasma NEFA not only in WT mice but also in
Fgf21-KO mice.

In addition, the increase in epi-WAT mass in Fgf21-KO mice
fed the low-protein diet but not in WT mice suggests that
increased FGF21 under protein malnutrition conditions pro-
motes lipolysis. This protective effect of FGF21 against obesity
is consistent with the results of a previous report using DIO
mice[30,31]. Moreover, although FGF21 has been shown to
suppress lipolysis in Fgf21-KO mice under fasting conditions,
it has also been shown to promote it during normal feeding[27].
Thus, FGF21 might suppress excessive lipolysis but is more
likely to stimulate lipolysis under normal feeding or protein-
restricted conditions in which excessive lipolysis does not
occur. In addition, the impairment of lipid uptake or lipogenesis
by FGF21 under conditions of protein malnutrition may explain
the increase in the epi-WAT mass in Fgf21-KO mice fed the 5P
diet. Feeding a low-protein diet also seemed to suppress fatty
acid oxidation slightly because plasma TKB levels decreased
in both WT and Fgf21-KO mice fed the low-protein diet, although
the difference was not statistically significant (two-way ANOVA,
effect of diet: P = 0-067). Because NEFA levels regulate ketone
body production[39], the decrease in NEFA level could be partly
responsible for the decrease in plasma TKB levels. Taken
together with the findings that FGF21 treatment increases
energy expenditure[30,31], stimulates thermogenic activation in
adipose tissues[40] and stimulates the browning of WAT[40], the
FGF21 increase observed in protein malnutrition may have
promoted NEFA mobilisation and usage in BAT or beige cells.

The molecular mechanism of liver lipid accumulation in
protein malnutrition is still under discussion; however, the 5P
diet promoted hepatic steatosis in both WT and Fgf21-KO mice,
as indicated by increases in liver TAG and cholesterol levels.
In addition, the increases in the lipid levels in the Fgf21-KO mice
were much greater than those in the WT mice. Therefore,
although it was insufficient for complete suppression, increased
FGF21 had a significant protective effect against hepatic stea-
tosis under conditions of protein malnutrition. FGF21 treatment
reportedly up-regulates some genes involved in cholesterol
excretion in the liver of mice fed a chow diet, and these
increases require insulin action[41]. Therefore, increased FGF21
due to protein malnutrition may stimulate cholesterol excretion
from the liver into the bile. Because protein deprivation
increases hepatic insulin sensitivity[42], increased insulin
signalling may synergistically increase this action during the
consumption of a low-protein diet. In addition, a recent study
reported that treating DIO mice with recombinant FGF21
reversed hepatic steatosis, likely in part due to the inhibition of
lipogenesis[31]. Therefore, in addition to exploring the mole-
cular pathway involved in lipid catabolism, further studies
should focus on lipid transport and lipogenesis.

In conclusion, the results of the present study showed that a
sufficient supply of protein suppresses FGF21, which is imme-
diately up-regulated in protein deprivation. Moreover, by using
an in vitro model, we newly demonstrated that this induction is
likely to be a direct effect of amino acid deprivation. Although
FGF21 reportedly suppresses IGF-I, we showed that growth
retardation and decreased IGF-I are not mediated by increased
FGF21 under conditions of protein malnutrition. Furthermore,
Fgf21-KO mice fed a low-protein diet showed greater epi-WAT
weight as well as hepatic TAG and cholesterol levels, which
demonstrated that FGF21 up-regulation has a protective effect against obesity and hepatic steatosis under protein malnutrition conditions.

Acknowledgements

The authors thank the members of Laboratory of Food Biochemistry at Meiji University for assistance with the animal experiments. We also acknowledge Dr Susan Hall (The University of North Carolina at Chapel Hill) for helping with the writing of the manuscript.

This work was supported by the Programme for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry and Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry (grant no. 25006A). The funder had no role in the design, analysis, or writing of this article.

The author contributions are as follows: Y. O., F. H., S.-I. T., H. K. and A. T. formulated the research questions. Y. O. and A. T. designed the study. M. K. and N. I. developed the analysis, or writing of this article.

The author contributions are as follows: Y. O., F. H., S.-I. T., H. K. and A. T. formulated the research questions. Y. O. and A. T. designed the study. M. K. and N. I. developed the analysis, or writing of this article.

There are no conflicts of interest.

Supplementary material

For supplementary material/s referred to in this article, please visit http://dx.doi.org/doi:10.1017/S0007114515002846

References


